Centre should intervene when patented medicines are sold at exorbitant rate: Kerala HC

This judgment directly intersects with the fundamental rights enshrined in the Indian Constitution. The court's assertion that the government must ensure access to healthcare, including life-saving treatments, is rooted in the expansive interpretation of Article 21 (Right to Life and Personal Liberty). The Supreme Court of India has consistently held that the right to health is an integral part of the right to a dignified life. Furthermore, this aligns with the Directive Principles of State Policy, specifically Article 47, which mandates the State to raise the level of nutrition and the standard of living and to improve public health. The High Court is essentially reminding the executive of its constitutional obligation to balance the protection of intellectual property with the paramount need for affordable healthcare for its citizens. For UPSC, this is a prime example of judicial intervention enforcing socioeconomic rights and the continuing evolution of Article 21.

The core governance issue here is the mechanism of Compulsory Licensing (CL) under the Patents Act, 1970. Chapter XVI of the Act, particularly Section 84, allows the government to grant a license to a third party to produce a patented product without the consent of the patent owner, provided certain conditions are met, such as the reasonable requirements of the public not being satisfied or the invention not being available at a reasonably affordable price. Section 92 further empowers the Central Government to issue a notification for compulsory licensing in circumstances of 'national emergency', 'extreme urgency', or 'public non-commercial use'. The Kerala High Court is advocating for the invocation of these provisions (specifically regarding non-commercial public use) when patented drugs become inaccessible due to cost. The pharmaceutical companies' defense—that an alternative (Palbociclib) was available—highlights the complex criteria the government must evaluate before granting a CL. The governance challenge lies in creating robust data collection mechanisms to monitor drug pricing and affordability, enabling timely intervention without stifling innovation.

From an economic standpoint, this case illustrates the classic market failure inherent in the pharmaceutical sector: a monopoly granted by a patent leading to exorbitant pricing that excludes a significant portion of consumers (inelastic demand for life-saving drugs). The patent system is designed to incentivize R&D by granting temporary exclusivity, but this must be balanced against public welfare. When prices are prohibitive, the state's intervention via the Patents Act, 1970 acts as a regulatory tool to correct this market failure. The use of 'public non-commercial use' provisions implies government procurement and distribution, potentially subsidized, to ensure access without directly competing in the commercial market. The economic consequence for UPSC candidates to consider is how aggressive use of compulsory licensing might impact Foreign Direct Investment (FDI) in the pharma sector and India's international obligations under the TRIPS Agreement (Trade-Related Aspects of Intellectual Property Rights). India must carefully navigate the flexibilities provided within TRIPS to protect public health while remaining an attractive destination for innovation.